Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Background Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1
RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular …
RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular …
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and …
TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich… - Circulation, 2019 - Am Heart Assoc
Background: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose
cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic …
cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic …
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta …
Background Recent large clinical trials have demonstrated cardiovascular benefits of similar
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
M Lugner, N Sattar, M Miftaraj, J Ekelund… - Cardiovascular …, 2021 - Springer
Background Major prospective randomized clinical safety trials have demonstrated
beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and …
beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and …
Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression
JM Rodriguez-Valadez, M Tahsin… - Diabetes …, 2023 - Am Diabetes Assoc
BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …
The future of new drugs for diabetes management
CJ Bailey, C Day - diabetes research and clinical practice, 2019 - Elsevier
The future of the newer classes of glucose-lowering drugs, namely dipeptidyl peptidase-4
(DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and …
(DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and …
Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real …
I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - Metabolites, 2022 - mdpi.com
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …
Cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: a systematic review and network …
Aims To compare the cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2
(SGLT 2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA s) in adults …
(SGLT 2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA s) in adults …
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
D Giugliano, M Longo, S Signoriello… - Cardiovascular …, 2022 - Springer
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-
transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network …
transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network …
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality …
Importance The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2)
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …
相关搜索
- receptor agonists meta analysis
- drug classes cardiovascular outcomes
- drug classes meta analysis
- cardiovascular outcomes meta analysis
- inhibitors and glucagon meta analysis
- diabetes mellitus meta analysis
- diabetes drugs meta regression
- diabetes drugs meta analysis
- cardiorenal outcomes meta analysis
- cardiovascular efficacy meta analysis
- sodium glucose meta analysis